For years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
The statistics regarding rare diseases speak for themselves: one of two patients diagnosed with a rare disease is a child; three of 10 children with a rare disease won’t live to see their fifth birthday; more than 400 million people suffer from a rare disease globally — greater than the population of the U.S. Fortunately, the drug development landscape for rare diseases is increasing exponentially. However, there are many challenges in conducting rare disease clinical trials, including small populations often spread across the globe, limited opportunities for study participation and replication of results in larger trials, and heterogeneous manifestations of disease and phenotypic presentations. The clinical manifestations are often not easily connected to a specific disease — on average, a rare disease patient visits seven specialists, and a correct diagnosis can take as long as six to eight years — and a lack of consensus on clinical outcome measures and poorly defined endpoints.
In this article, Shipra Patel, M.D., Global TA Section Head, Endocrinology, Parexel, discusses how she strives to overcome these challenges daily.
Studying rare cancer patient populations using integrated genomic and real-world data
Aug 30, 2023
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Insights from the 2022 R&D Innovation Survey
Feb 17, 2023
Why Rare Disease Therapeutics Need Early Market Access Planning
Jan 4, 2023
Rachel Smith joins Parexel as Executive Director and Head of the Rare Disease, Center of Excellence
Aug 10, 2022
China's Market Approval Policy and Medical Insurance Payment System for Rare Disease
Jul 21, 2022
EU Orphan Drug Designation – overcoming regulatory challenges
Jul 20, 2022
Parexel names first Patient Ambassador
Jun 17, 2022
Overview of China's Market Approval Policy Med Insurance Payment System
Apr 7, 2022